Literature DB >> 9466988

Defects in neurofibromatosis 2 protein function can arise at multiple levels.

D H Gutmann1, R T Geist, H m Xu, J S Kim, S Saporito-Irwin.   

Abstract

Neurofibromatosis 2 (NF2) is an inherited cancer syndrome resulting from mutations in the NF2 tumor suppressor gene. Analysis of NF2 mutations has revealed some general genotype-phenotype correlations. Severe disease has been associated with mutations that produce a premature termination while more mild disease has been associated with missense mutations. Here, we provide experimental proof for these genotype-phenotype correlations by demonstrating that nonsense mutations fail to produce stable merlin protein while missense mutations result in the generation of merlin proteins defective in negative growth regulation. This inability to suppress cell growth may result from defects in the function of merlin at several levels, including failure to form an intramolecular complex. Based on these findings, we propose a model for merlin growth suppression that provides a framework for analyzing NF2 patient mutations and merlin function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466988     DOI: 10.1093/hmg/7.3.335

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  25 in total

1.  Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.

Authors:  S D Yogesha; Andrew J Sharff; Marco Giovannini; Gerard Bricogne; Tina Izard
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

2.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.

Authors:  Rong Rong; Xiaoling Tang; David H Gutmann; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

Review 3.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 4.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

5.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein.

Authors:  M Giovannini; E Robanus-Maandag; M Niwa-Kawakita; M van der Valk; J M Woodruff; L Goutebroze; P Mérel; A Berns; G Thomas
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

6.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Authors:  H Morrison; L S Sherman; J Legg; F Banine; C Isacke; C A Haipek; D H Gutmann; H Ponta; P Herrlich
Journal:  Genes Dev       Date:  2001-04-15       Impact factor: 11.361

7.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

8.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 9.  Phosphorylation of merlin regulates its stability and tumor suppressive activity.

Authors:  Keqiang Ye
Journal:  Cell Adh Migr       Date:  2007-10-22       Impact factor: 3.405

10.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

Authors:  Dominique Lallemand; Marcello Curto; Ichiko Saotome; Marco Giovannini; Andrea I McClatchey
Journal:  Genes Dev       Date:  2003-04-14       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.